Expedition Therapeutics-preview

Expeditiontx

Expedition Therapeutics

Private

San Francisco, CaliforniaHealthcare & Life Scienceshttps://expeditiontx.com

Last Round

Series A

Oct 9, 2025

Est. Valuation

$650M

Total Funding Raised

$165M

Momentum Score

75 /100

Company Overview

Expedition Therapeutics is a biotechnology company developing novel therapies for serious inflammatory and respiratory diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Non-AI

Keywords

COPD treatmentDPP1 inhibitorsmall molecule therapeuticsclinical-stage biotechfirst-in-class therapydrug developmentoral therapyneutrophilic inflammationpharma partnershipsinflammatory disease treatmentrespiratory disease treatmentdrug licensingdipeptidyl peptidase 1 inhibitorphase 2 clinical trialchronic obstructive pulmonary disease

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Expedition Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Expedition Therapeutics Funding Rounds

Historical fundraising activity

Round	Date	Amount Raised	Valuation	Investors	Sources
Series A	Oct 9, 2025

View all Funding Rounds

Key People

Founding team and executive leadership

Yi Larson

President And CEO

Executive Team

Expedition Therapeutics Investors

Notable investors and investment history

Investor	Rounds
Balyasny Asset Management L.P.	Series A
Lake Bleu Capital	Series A
Forbion	Series A
Venrock Healthcare Capital Partners	Series A
Logos Capital	Series A
Novo Holdings	Series A
BVF Partners L.P.	Series A

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Apr 24, 2026
Grew 86% QoQ, from 7 to 13 employees.
Apr 20, 2026
Monthly visitors grew 155% MoM, reaching 1.4K.

View all signals

Expedition Therapeutics Filings

SEC and related filings with document metadata.

Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Expedition Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Expedition Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Francisco, California

Employee Range13

Year Founded2024

Last FundingOct 9, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.